MarketPulse
R

$RVMDW

11 articles found
7 positive
1 negative
3 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Revolution Medicines

Revolution Medicines' Daraxonrasib Achieves NEJM Publication on Pancreatic Cancer Progress

Revolution Medicines published Phase 1/2 daraxonrasib data in NEJM, demonstrating promising activity in RAS mutant pancreatic cancer and supporting Phase 3 trial initiation.
RVMDRVMDWclinical trial resultspancreatic cancer
The Motley FoolThe Motley Fool··Seena Hassouna

SCHA vs. ISCB: Small-Cap ETF Showdown Hinges on Sector Bets and Risk Appetite

Identical-cost small-cap ETFs $SCHA and $ISCB diverge sharply: $SCHA's $22B asset base and tech tilt delivered 47.1% five-year returns versus $ISCB's 38.4%, with choice hinging on sector preferences and drawdown tolerance.
ALBALBpARVMDRVMDWLITE+2portfolio diversificationexpense ratio
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Revolution Medicines Advances KRAS G12D Lung Cancer Drug With 52% Response Rate

Revolution Medicines reports promising Phase 1 data for zoldonrasib, showing 52% response rate in previously treated KRAS G12D lung cancer patients with manageable safety profile.
RVMDRVMDWPhase 1 clinical trialoncology
BenzingaBenzinga··Nabaparna Bhattacharya

Quantum, Nuclear, and Fintech Surge: Ten Large-Caps Rally on Sector Tailwinds

Large-cap stocks rallied sharply April 13-17, with IonQ (+62.86%), Oklo (+33.35%), and Robinhood (+33.22%) leading gains driven by DARPA contracts, nuclear momentum, and crypto strength.
OKLOAFRMIONQIONQ.WSRVMD+11cryptocurrencynuclear power
BenzingaBenzinga··Na

Revolution Medicines Raises $2.2B in Upsized Offerings to Fuel R&D Pipeline

Revolution Medicines closes $2.2B concurrent offerings, including equity and convertible notes, to accelerate drug development and commercialization.
RVMDRVMDWclinical developmentpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Revolution Medicines Raises $2B in Upsized Stock and Convertible Offerings

Revolution Medicines raises $2.0 billion via 10.56M shares at $142/share and $500M convertible notes for R&D and commercialization.
RVMDRVMDWclinical developmentpublic offering
BenzingaBenzinga··Vandana Singh

Revolution Medicines Soars 40% on Pancreatic Cancer Breakthrough, Despite Merck Deal Collapse

Revolution Medicines surges 40% after Phase 3 trial shows daraxonrasib doubles survival in metastatic pancreatic cancer versus chemotherapy.
MRKRVMDRVMDWPhase 3 trialclinical trial results
BenzingaBenzinga··Vandana Singh

Merck's $6.7B Terns Deal Could Attract Rival Bidders as Patent Cliff Looms

Merck agrees to acquire Terns Pharmaceuticals for $6.7B to strengthen pipeline before Keytruda's 2028 patent expiry, but analysts suggest competing bids may emerge.
MRKNVSRVMDRVMDWTERNacquisitionM&A
The Motley FoolThe Motley Fool··Andy Gould

Swiss Biotech Fund Doubles Down on Relay With $6M Stake Bet

Swiss biotech fund Nextech Invest increases Relay Therapeutics stake by $6.1M, signaling institutional confidence in company's computational platform and clinical pipeline.
RVMDRVMDWRLAYXBIIBBinstitutional buyingbiotech investment
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Hedge Fund Exits Protagonist Position Despite 120% Stock Surge

BVF Partners liquidated its $170M Protagonist stake despite 120% gains, likely due to changing risk profile as company awaits FDA decision on blood disorder treatment.
PTGXKYMRRVMDRVMDWclinical-stage biotechhedge fund liquidation
The Motley FoolThe Motley Fool··Jonathan Ponciano

BVF's $52M Stake in Disc Medicine Signals Confidence Despite Regulatory Hurdles

BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.
KYMRRVMDRVMDWIRONFDA approvalclinical trial